AZD3839   Click here for help

GtoPdb Ligand ID: 6931

Synonyms: AZD 3839 | AZD-3839
Compound class: Synthetic organic
Comment: AstraZeneca BACE1 inhibitor AZD3839 recently progressed into Phase 1 clinical trials for Alzheimer's Disease.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 76.72
Molecular weight 433.15
XLogP 3.48
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES FC(c1nccc(c1)C1(NC(c2c1cccc2F)N)c1cccc(c1)c1cncnc1)F
Isomeric SMILES FC(c1nccc(c1)[C@@]1(NC(c2c1cccc2F)N)c1cccc(c1)c1cncnc1)F
InChI InChI=1S/C24H18F3N5/c25-19-6-2-5-18-21(19)23(28)32-24(18,17-7-8-31-20(10-17)22(26)27)16-4-1-3-14(9-16)15-11-29-13-30-12-15/h1-13,22-23,32H,28H2/t23?,24-/m0/s1
Bioactivity Comments
AZD3839 inhibited Aβ and sAPPβ release from modified and wild-type human SH-SY5Y cells, mouse N2A cells, mouse and guinea pig primary cortical neurons. Selectivity against BACE2 and cathepsin D was 14 and >1000-fold, respectively. Dose- and time-dependent lowering of plasma, brain, and cerebrospinal fluid Aβ levels in mouse, guinea pig, and a non-human primate were demonstrated. Inhibited BACE1 activity in a biochemical fluorescence resonance energy transfer (FRET) assay. [1]
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
beta-secretase 1 Primary target of this compound Hs Inhibitor Competitive 7.6 pKi - 1
pKi 7.6 (Ki 2.61x10-8 M) [1]